AP110 Diagnostic Aspects of Pulmonary Adenocarcinoma
8:00–11:30 am
3.0 CME CREDITS
Lung cancer is the most frequent and fatal malignancy worldwide, with adenocarcinoma the most prevalent and complex subtype. The current classification fails to address the complexity of disease encountered in surgically resected tumors or reflect the clinical significance of tumor heterogeneity. The course will discuss new proposals, including in situ versus invasive disease, and the bronchioloalveolar carcinoma issue. Faculty will address small biopsy classification of lung cancer, which requires improved diagnostic specificity and accuracy to target emerging therapies for nonsmall cell lung cancer subtypes. Molecular analysis is also a crucial adjunct in characterizing lung adenocarcinoma and in facilitating appropriate therapy choices. Discussion will include diagnostic integration of analyses such as EGFR, KRAS, ALK and other mutations.
You will learn to:
- Discuss the background and rationale for changes in lung adenocarcinoma classification
- Recognize the patterns of lung adenocarcinoma
- Apply ancillary techniques, including immunohistochemical staining, to refine the diagnosis of lung cancer on small tissue biopsies
- Discuss the role of molecular analysis as part of adenocarcinoma diagnosis
Faculty
Keith M. Kerr, MBChB, IFCAP
Cosponsored by 